The global non-injectable insulin market size accounted for USD 1,800 million in 2024 and is expected to exceed around USD 6,440 million by 2034, growing at a CAGR of 13.6% from 2024 to 2034.
The demand for non-injectable insulin is rising as diabetes becomes more commonplace globally and people want a more convenient and comfortable form of therapy. Patient preferences and the uptake of non-injectable insulin are expected to be influenced by cultural factors and healthcare professionals' openness to trying new therapies. The market for non-injectable insulin, which includes transdermal patches, oral insulin, and inhalable insulin, offers simple and less complicated substitutes for conventional insulin injections in the pharmaceutical sector. The non-injectable insulin market is expanding as a result of novel advancements in drug delivery technology that have produced more reliable and efficient non-injectable insulin substitutes.
Prominent businesses are investigating oral insulin formulations that are resistant to the circumstances of the digestive system. By providing a painless and pleasant substitute for needles, they have the potential to completely transform the treatment of diabetes. Due to needle phobia and everyday inconveniences, diabetic patients seek non-injectable insulin substitutes, which forces pharmaceutical companies to make investments in novel solutions. The market is expanding as a result of regulatory agencies like the FDA reviewing and approving new insulin products. To further the development of insulin-delivery products, pharmaceutical corporations are working with healthcare providers, IT firms, and research groups.